Sapient Capital LLC Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sapient Capital LLC cut its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,015 shares of the biotechnology company’s stock after selling 131 shares during the period. Sapient Capital LLC’s holdings in Sarepta Therapeutics were worth $1,297,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its stake in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 87 shares in the last quarter. Vanguard Capital Wealth Advisors increased its stake in shares of Sarepta Therapeutics by 3.8% during the 4th quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock worth $236,000 after purchasing an additional 90 shares in the last quarter. DMC Group LLC increased its stake in shares of Sarepta Therapeutics by 2.9% during the 3rd quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock worth $400,000 after purchasing an additional 93 shares in the last quarter. Cary Street Partners Investment Advisory LLC increased its stake in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 154 shares in the last quarter. Finally, Natixis Advisors L.P. increased its stake in shares of Sarepta Therapeutics by 0.6% during the 3rd quarter. Natixis Advisors L.P. now owns 26,026 shares of the biotechnology company’s stock worth $3,155,000 after purchasing an additional 160 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 1,200 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.30, for a total value of $153,960.00. Following the transaction, the chief financial officer now owns 39,114 shares of the company’s stock, valued at approximately $5,018,326.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $123.25, for a total value of $1,848,750.00. Following the transaction, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,815,030. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Ian Michael Estepan sold 1,200 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the completion of the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at approximately $5,018,326.20. The disclosure for this sale can be found here. Insiders have sold a total of 22,096 shares of company stock worth $2,739,419 in the last quarter. 7.40% of the stock is owned by insiders.

Sarepta Therapeutics Trading Down 1.7 %

Shares of SRPT traded down $2.14 during mid-day trading on Tuesday, reaching $126.66. The company had a trading volume of 1,092,767 shares, compared to its average volume of 998,905. The stock has a market cap of $11.97 billion, a price-to-earnings ratio of -20.70 and a beta of 0.94. The firm has a fifty day simple moving average of $125.99 and a 200-day simple moving average of $110.36. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $159.89. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. The company had revenue of $396.80 million for the quarter, compared to analyst estimates of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. Sarepta Therapeutics’s revenue for the quarter was up 53.6% on a year-over-year basis. During the same quarter last year, the business earned ($1.24) EPS. On average, sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of recent research reports. Wedbush reissued an “outperform” rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Royal Bank of Canada raised their price objective on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. Cantor Fitzgerald reissued a “neutral” rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Evercore ISI raised their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a research report on Tuesday, February 20th. Finally, BMO Capital Markets assumed coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 31st. They set an “outperform” rating and a $170.00 target price on the stock. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $156.60.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.